Navigation Links
Cato Research Celebrates 25 Years of Successful Life Science Research and Development
Date:9/18/2013

Durham, NC (PRWEB) September 18, 2013

Cato Research (CATO) celebrates 25 years of dedicated service to the life science industry. CATO has navigated decades of successful health care research and development, bringing products to the market that ultimately may help those who need them the most.

Headquartered in the Research Triangle Park of North Carolina, CATO is a global, competitive contract research organization that includes an investment arm, Cato BioVentures. Together, CATO and Cato BioVentures have helped biotech companies, pharmaceutical companies, and investors develop their products and bring them to market. CATO has a proven track record of effective collaboration, saving time and reducing cost without jeopardizing product quality while meeting the clinical and regulatory project challenges. The combination of these attributes and capabilities makes for many successful years of business.

“It is truly rewarding to be able to reflect over the past 25 years, cherishing the relationships we have built, and proud of the growth and success we have experienced. Most important to us are the patients we have been able to help by bringing products to the market that have made a difference to their lives. We are thankful and look forward to servicing this industry many more years to come,” says Lynda Sutton, President and cofounder of Cato Research and Cato BioVentures.

Cofounded in 1988 by Allen Cato, M.D., Ph.D., and Lynda Sutton, CATO will celebrate its 25th year by holding several wine tastings throughout the United States at its many office locations. These events will include evenings filled with highly rated wines and delightful hors d'oeuvres, accompanied with lots of mingling. The celebration begins in Boston, Massachusetts, and will conclude in Durham, North Carolina. More information is detailed below.

Celebrate with CATO at the following locations and dates:

Cato Research Boston office
Boston, MA USA
Wednesday, 18 September 2013

Cato Research Washington, D.C. office
Washington, D.C. USA
Tuesday, 08 October 2013

Cato Research San Diego office
San Diego, CA USA
Tuesday, 15 October 2013

FINALE: Cato Research Durham office
Durham, NC USA
Tuesday, 29 October 2013

More information and registration links can be found at:
http://www.cato.com/marketing/2013/25-Year-Wine-Tasting_Cato-Research-Boston2013.html

About Cato BioVentures
Cato BioVentures is the venture capital affiliate of Cato Research, a global contract research and development organization (CRO). For over 20 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotechnology and pharmaceutical companies to advance a robust portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, Cato BioVentures has invested its CRO Service Capital™ in innovative therapeutics, medical devices, and stem cell technologies that improve the pharmaceutical industry’s research and development productivity. If strategic outsourcing for development, regulatory, and clinical support is a core component of a company’s business plan, then Cato BioVenture’s investment model can make a positive difference in that company’s overall success.

About Cato Research
Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, Cato Research consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing its clients’ products to market with speed and cost-effectiveness.

For more information, please contact:

Cato Research
Phone: 919-361-2286
http://www.cato.com
# # #

Read the full story at http://www.prweb.com/releases/2013/9/prweb11133227.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. UCLA researchers smartphone microscope can detect a single virus, nanoparticles
2. Lisa Niemi Swayze And The Pancreatic Cancer Action Network Join More Than 160 Organizations In Asking Congress To Protect Medical Research Funding
3. Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
4. Quorum IRB Board Chair to Speak at South Korean Research Summit
5. MarketResearchReports.Biz: China Orthopedic Instrument Industry Report, 2013 - 2015 - New Industry Report
6. New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline
7. Crowdfunding Expert Kendall Almerico Discusses Scientists Using Crowdfunding to Replace Research Grants
8. Intrexon and Rentokil Enter into Research and Development Agreement to Explore a New Generation of Highly-Effective, Sustainable Pest Controls
9. Elsevier and Australasian Research Management Society Honor Promising Young Scientists for their Work in Academic Research
10. Hydrofluoric & Aminoacetic Acid (Gly) Industry 2013 China and Global Analysis in New Research Report at Deepresearchreports.com
11. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
(Date:3/23/2017)... New York , March 23, 2017 ... blood plasma products and derivatives market is fragmented due to the presence ... players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete ... leader, these three companies, collectively, held more than 76% of this ... ...
(Date:3/23/2017)... YORK , March 23, 2017 ... look at four equities in the Biotech industry: Sangamo ... Synthetic Biologics Inc. (NYSE MKT: SYN), and Regulus Therapeutics ... 21 st , 2017, Credit Suisse upgraded its rating on ... by downloading their free report at: ...
(Date:3/22/2017)... TARRYTOWN, N.Y. , March 22, 2017 Regeneron ... among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK ... in the U.K. Biobank resource. The initiative will enable researchers ... of new medicines for a wide range of serious and ... ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
Breaking Biology News(10 mins):